Activity Overview
The Advanced Rheumatology Course is a 19-activity series for advanced practice providers and other professionals who need a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumatic disease, develop strategies to integrate NP/PAs into rheumatology practice, and improve access to care for patients. The advanced information will help experienced practice providers function well in rheumatology and foster inter-professional collaboration.
In this activity, you will review the epidemiology, clinical features, differential diagnoses, treatment options, and outcomes concerning vasculitis and other vasculitides.
Advanced Rheumatology Course Series
This activity is part of a series. See all activities in the series below.
Activity 1: Musculoskeletal Structure And Function And Inflammation And Immunity
Activity 16: Osteoporosis And Other Metabolic Bone Disorders
Activity 17: Comprehensive Overview of Juvenile Idiopathic Arthritis
Activity 18: A Comprehensive Review of Pediatric Connective Tissue Diseases
Target Audience
Advanced practice nurses, physician assistants, Rheumatology fellows-in-training, residents, students, primary care providers and researchers may also benefit.
Learning Objectives
Upon completion of this activity, participants should be able to:
Define vasculitis and describe the clinical features and the spectrum of disease entities in which vasculitis is seen
Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome for polymyalgia rheumatica (PMR)
Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome of giant cell arteritis (GCA)
Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome of granulomatosis with polyangiitis (GPA)
Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome of polyarteritis nodosa
Describe cutaneous vasculitis and its potential causes, diagnostic evaluation, and therapeutic principles
CE & MOC Information
Credit must be claimed by August 19, 2029, at 11:59 PM ET.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
ACPE credits are reported to CPE Monitor monthly NABP e-PID and date of birth provided when you claimed credit and should appear in your CPE dashboard within 60 days of credit claiming.
The following credit types must be self-reported to the appropriate board: CME, AAPA, AANC, AWSB ACE, and APA. The certificate is a record of your activity completion.
All participating healthcare professionals should claim only the credit commensurate with the extent of their participation in this activity.
Available Credit
CME: 1.25 AMA PRA Category 1 Credit(s)™
AAPA: 1.25 AAPA Category 1 CME™ Credits
ACPE: 1.25 CPE Credits
ANCC: 1.25 Contact Hours
ICPE: 1.25 IPCE Credits
Designation Statements
Joint Accreditation
In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Number: 0003797
See the ACR's CE Mission Statement. For more information, download the AMA PRA Booklet.
AMA
The ACR designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA
The ACR has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until August 19, 2029. PAs should only claim credit commensurate with the extent of their participation.
ACPE
The ACR designates this enduring activity for a maximum of 1.25 hours of ACPE contact hour(s). Pharmacists and pharmacy technicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit will be uploaded to the NABP CPE Monitor® within 60 days after activity completion. Per ACPE rules, ACR does not have access nor the ability to upload credits requested after the evaluation closes. It is the responsibility of the pharmacist or pharmacy technician to provide the correct information (NABP ID and date of birth (MMDD)) to receive credit. The Universal Activity Number(s) for this activity is JA0003797-0000-26-013-H01-P.
All continuing pharmacy education credits must be claimed within 60 days of the enduring activity you attend. To be sure your CE is accepted inside of ACPE's 60-day window, plan to process your CE before August 19, 2029, at 11:59 PM ET. After the 60-day deadline, ACR will no longer be able to award credit for this activity.
ANCC
The ACR designates this activity for a maximum of 1.25 ANCC contact hours.
IPCE
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Financial Relationships Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Education (CE) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at http://accme.org .
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CE activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CE activity.
Nature of Financial Relationships
All individuals involved or able to influence the content of this accredited activity have disclosed to the editorial team and audience any/all financial or other relationship(s) including, but not limited to:
Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
Faculty
Authors/Planners:
Anisha Dua, MD - AbbVie/Abbott (2; Amgen (2, 5); AtsraZeneca (2); GSK (2); Sanofi (2); Novartis (2, 5); Zenas (2); RRF (5)
Brian Jaros, MD - Amgen (2, 5, 6); AbbVie (2, 6); AtsraZeneca (2); Zenas (2)
Josh Waytz, MD – No relevant financial relationships to disclose
Editors and Reviewers:
Marcy Bolster, MD – AbbVie (2); Corbus Pharmaceuticals (2); Cumberland (2); Genentech (2); Gilead Sciences (5); Johnson & Johnson (1); Pfizer (2)
Christopher Estes, NP, RhMSUS – Johnson & Johnson (1)
Paul Monach, MD, PhD – Celgene (1); Chemocentryx (6); Kiniksa (6)
Anneke Smith – No relevant financial relationships to disclose
Planners:
Kendra Allen - No relevant financial relationships to disclose
Rachelle Anness - No relevant financial relationships to disclose
Maura Iversen, PT, DPT, ScD, MPH, FNAP, FAPTA - Johnson & Johnson (11)
Andrew Laster, MD, FACR, MACR - Amgen (2)
Janell Leigh Martin - No relevant financial relationships to disclose
Acknowledgement of Financial Support
The project described is, in part, supported by the Centers for Disease Control and Prevention under Cooperative Agreement Number NU58DP006908, Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of its developers/authors. Points of view or opinions do not, therefore, necessarily represent official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.
Educational Activity Policies
See ACR educational activity policies, including the online enduring activity refund policy.